Search hospitals
>
Missouri
>
Kansas City
Saint Luke's Hospital of Kansas City
Claim this profile
Kansas City, Missouri 64111
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Heart Failure
Conducts research for Stroke
Conducts research for Coronary Artery Disease
437 reported clinical trials
44 medical researchers
Summary
Saint Luke's Hospital of Kansas City is a medical facility located in Kansas City, Missouri. This center is recognized for care of Breast Cancer, Lung Cancer, Heart Failure, Stroke, Coronary Artery Disease and other specialties. Saint Luke's Hospital of Kansas City is involved with conducting 437 clinical trials across 553 conditions. There are 44 research doctors associated with this hospital, such as Michael Gibson, Timothy Pluard, Janakiraman Subramanian, and Keith Allen, MD.
Area of expertise
Breast Cancer
Saint Luke's Hospital of Kansas City has run 40 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Saint Luke's Hospital of Kansas City has run 37 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Michael Gibson
Vanderbilt University/Ingram Cancer Center
5 years of reported clinical research
Timothy Pluard
Saint Luke's Cancer Institute LLC
2 years of reported clinical research
Janakiraman Subramanian
Saint Luke's Hospital of Kansas City
6 years of reported clinical research
Keith Allen, MD
Saint Luke's Hospital of Kansas City
4 years of reported clinical research
Clinical Trials running at Saint Luke's Hospital of Kansas City
Breast Cancer
Lung Cancer
Heart Failure
Breast cancer
Amyloidosis
Pancreatic Cancer
Pancreatic Carcinoma
Non-Small Cell Lung Cancer
Colorectal Cancer
Heart Disease
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are being observed for cardiac toxicity. The largest cohort (currently open to accrual) is observational, and contains patients who are taking a beta blocker, ACE inhibitor, or ARB as well as their trastuzumab-based treatment. The goal is to understand how common cardiac problems are in this group of patients at high risk. The smaller cohort (currently closed to accrual) is randomized. Patients in this second cohort are randomized to either carvedilol or no treatment, with the goal of seeing whether carvedilol (used to treat heart failure and high blood pressure) may prevent the heart from side effects of chemotherapy.
Recruiting
2 awards
Phase 3
23 criteria
PF-07220060 + Letrozole
for Breast Cancer
The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or progesterone to grow) * HER2-negative (cells that have a small amount or none of a protein called HER2 on their surface); * locally advanced (that has spread from where it started to nearby tissue or lymph nodes) or metastatic disease (the spread of cancer to other places in the body) * who have not received any prior systemic anti-cancer treatment for advanced/metastatic disease. Approximately half of the participants will receive PF-07220060 plus letrozole while the other half of participants will receive the investigator's choice of treatment plus letrozole. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.
Recruiting
2 awards
Phase 3
4 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting
2 awards
Phase 3
19 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Saint Luke's Hospital of Kansas City?
Saint Luke's Hospital of Kansas City is a medical facility located in Kansas City, Missouri. This center is recognized for care of Breast Cancer, Lung Cancer, Heart Failure, Stroke, Coronary Artery Disease and other specialties. Saint Luke's Hospital of Kansas City is involved with conducting 437 clinical trials across 553 conditions. There are 44 research doctors associated with this hospital, such as Michael Gibson, Timothy Pluard, Janakiraman Subramanian, and Keith Allen, MD.
Where is Saint Luke's Hospital of Kansas City located?
**Saint Luke's Hospital of Kansas City** - **Address:** 4401 Wornall Rd, Kansas City, MO 64111. - **Parking:** Free patient and visitor parking available in designated areas, including Lot 13 and Parking A at 43rd Street, Entrance C.
Who should I call to ask about financial aid or insurance network?
**Saint Luke's Hospital of Kansas City - Financial Assistance and Insurance Contact Information** **Financial Assistance:** - **Phone:** 816-932-5678 or 888-581-9401 (toll-free) - **Email:** slhsbilling@saintlukeskc.org - **Website:** [Saint Luke's Financial Assistance](https://www.saintlukeskc.org/saint-lukes-hospital-kansas-city-financial-assistance) **Insurance:** - **Phone:** 832-355-3081 - **Website:** [St. Luke's Insurance Information](https://www.stlukeshealth.org/patients-visitors/patients/billing-insurance) **General Billing Inquiries:** - **Phone:** 314-576-8100 or 888-924-9200 (toll-free) - **Fax:** 314-576-8180 - **Address:** St. Luke's Hospital, Attn: Billing Department, 232 S. Woods Mill Road, Chesterfield, MO 63017 For assistance with financial aid applications, insurance queries, and billing concerns, please use the above contacts.
What insurance does Saint Luke's Hospital of Kansas City accept?
Saint Luke's Hospital of Kansas City accepts a wide range of insurance plans, ensuring comprehensive coverage for various patient needs. Among the accepted insurances are Aetna (including Aetna Select HMO, Aetna Choice POS II, and Aetna Missouri Preferred), Blue Cross Blue Shield (including Pathway X, Blue Choice Preferred, and Blue Access), Cigna, Humana, United Healthcare, and many more, covering both national and local plans. It's advised to verify with your insurance carrier that Saint Luke's is an in-network facility and that the planned services are covered by your plan before scheduling any appointments.
What awards or recognition has Saint Luke's Hospital of Kansas City received?
Saint Luke's Hospital of Kansas City is renowned for its healthcare excellence, having been ranked 35th nationally by Consumer's Checkbook in 2002. The hospital boasts a dedicated Office of Research Services, supporting a wide range of research activities. Its research mission emphasizes clinical, translational, and outcomes research to enhance patient care and population health.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.